Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program

Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program

Abstract Background The incidence of Merkel cell carcinoma (MCC), a rare form of skin cancer with a poor prognosis, has increased in Italy in recent decades. Avelumab, an anti-programmed death ligand 1 monoclonal antibody, is approved for the treatment of metastatic MCC (mMCC) based on the results o...

Full description

Bibliographic Details
Main Authors: Giovanni Grignani, Vanna Chiarion Sileni, Carmine Pinto, Roberta Depenni, Nicola Fazio, Luca Galli, Dario Giuffrida, Carlo Carnaghi, Domenico Ciliberto, Domenico C. Corsi, Paola Queirolo, Elena Benincasa, Filippo Venturini, Gennaro Fazzi, Nuno Costa, Paolo Antonio Ascierto
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Journal of Translational Medicine
Subjects:
Avelumab
Merkel cell carcinoma
Second line
Expanded access program
PD-L1
Online Access:https://doi.org/10.1186/s12967-021-02730-8

Internet

https://doi.org/10.1186/s12967-021-02730-8

Similar Items